Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced that it has received separate clinical trial approvals from the National Medical Products Administration (NMPA) for two of its drug candidates, SHR-3276 and HRS2398. SHR-3276 is slated for study in patients with general advanced solid tumors, while HRS2398 will be investigated in those with general advanced malignant tumors.
SHR-3276 is a novel therapeutic biological product designed to enhance the immune system’s capabilities by boosting the function of immune cells and inducing a synergistic anti-tumor response. According to Hengrui’s press release, there is no similar product approved globally, indicating the potential for SHR-3276 to be a groundbreaking treatment. Hengrui has invested 13.22 million RMB in the development of this molecule.
HRS2398 is an oral ATR inhibitor with a unique mechanism of action that involves exacerbating DNA double-strand damage, thereby inhibiting cell proliferation and exhibiting anti-tumor effects. This early clinical stage product, which also has no equivalent on the global market, could be a first-in-class treatment. Hengrui has spent 40.29 million RMB on the development of HRS2398 to date.- Flcube.com
